Kristian W Pajtler

List of Publications by Year in Descending Order

102 papers	5,915 citations	32 h-index	76 g-index
115 ext. papers	8,319 ext. citations	8.8 avg, IF	5.1 L-index

#	Paper	IF	Citations
102	SIOP Ependymoma I: Final results, long term follow-up and molecular analysis of the trial cohort: A BIOMECA Consortium Study.. *Neuro-Oncology*, **2022**,	1	1
101	Controversies and challenges in the management of paediatric non-rhabdomyosarcoma soft tissue sarcomas.. *The Lancet Child and Adolescent Health*, **2022**,	14.5	2
100	The treatment approach to pediatric non-rhabdomyosarcoma soft tissue sarcomas: a critical review from the INternational Soft Tissue SaRcoma ConsorTium.. *European Journal of Cancer*, **2022**, 169, 10-19	7.5	1
99	EPEN-18. Oncogenic 3D genome conformations identify novel therapeutic targets in ependymoma. *Neuro-Oncology*, **2022**, 24, i42-i42	1	
98	EPEN-19. Impact of molecular classification on prognosis in children and adolescents with spinal ependymoma: Results from the HIT-MED database. *Neuro-Oncology*, **2022**, 24, i42-i43	1	
97	MODL-04. Drug screening in Disorders with Abnormal DNA Damage Response/Repair (DADDR) andin vivo validation. *Neuro-Oncology*, **2022**, 24, i168-i169	1	
96	MEDB-60. Medulloblastoma with extensive nodularity mimics cerebellar development and differentiates along the granular precursor lineage. *Neuro-Oncology*, **2022**, 24, i120-i120	1	
95	MEDB-38. Significance of CSF cytology and neurologic deterioration in relapsed medulloblastomas in the German HIT-REZ-97/-2005 Studies and the HIT-REZ-Register. *Neuro-Oncology*, **2022**, 24, i113-i114	1	
94	MEDB-14. Clinical outcome of pediatric medulloblastoma patients with Li-Fraumeni syndrome. *Neuro-Oncology*, **2022**, 24, i107-i107	1	
93	OTHR-32. The Pediatric Targeted Therapy 2.0 registry: robust molecular diagnostics for precision oncology. *Neuro-Oncology*, **2022**, 24, i154-i154	1	
92	MODL-07. DNA methylation-based biobank of murine models for pediatric tumors. *Neuro-Oncology*, **2022**, 24, i169-i170	1	
91	EPEN-28. Oncogenic dependency of pediatric ependymomas on extracellular vesicle pathways. *Neuro-Oncology*, **2022**, 24, i45-i45	1	
90	HGG-61.Landscape of cancer predisposition in pediatric high-grade glioma. *Neuro-Oncology*, **2022**, 24, i76-i76	1	
89	EPEN-09. Multi-omics characterization of the blood-brain barrier in molecular groups of ependymoma. *Neuro-Oncology*, **2022**, 24, i40-i40	1	
88	PATH-11. Detection of genetic and epigenetic alterations in Liquid Biopsies from pediatric brain tumor patients. *Neuro-Oncology*, **2022**, 24, i160-i161	1	
87	Serial assessment of measurable residual disease in medulloblastoma liquid biopsies. *Cancer Cell*, **2021**, 39, 1519-1530.e4	24.3	13
86	Systemic chemotherapy of pediatric recurrent ependymomas: results from the German HIT-REZ studies. *Journal of Neuro-Oncology*, **2021**, 155, 193-202	4.8	2

85	Local and systemic therapy of recurrent ependymoma in children and adolescents: short- and long-term results of the E-HIT-REZ 2005 study. *Neuro-Oncology*, **2021**, 23, 1012-1023	1	10
84	Liquid biopsies als neue Diagnostikplattform in der pädiatrischen Onkologie. *Onkologe*, **2021**, 27, 458-463	0.1	
83	ZFTA-RELA Dictates Oncogenic Transcriptional Programs to Drive Aggressive Supratentorial Ependymoma. *Cancer Discovery*, **2021**, 11, 2200-2215	24.4	16
82	Translocations Constitute Ependymoma Chromatin Remodeling and Transcription Factors. *Cancer Discovery*, **2021**, 11, 2216-2229	24.4	13
81	Cross-Species Genomics Reveals Oncogenic Dependencies in ZFTA/C11orf95 Fusion-Positive Supratentorial Ependymomas. *Cancer Discovery*, **2021**, 11, 2230-2247	24.4	20
80	Targeting fibroblast growth factor receptors to combat aggressive ependymoma. *Acta Neuropathologica*, **2021**, 142, 339-360	14.3	4
79	Cancer predisposition in pediatric neuro-oncology-practical approaches and ethical considerations. *Neuro-Oncology Practice*, **2021**, 8, 526-538	2.2	1
78	From Sampling to Sequencing: A Liquid Biopsy Pre-Analytic Workflow to Maximize Multi-Layer Genomic Information from a Single Tube. *Cancers*, **2021**, 13,	6.6	3
77	Bioanalysis of selinexor in mouse plasma micro-samples utilizing UPLC-MS/MS. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2021**, 1176, 122781	3.2	1
76	EPEN-03. ZFTA/C11ORF95 FUSIONS DRIVE SUPRATENTORIAL EPENDYMOMA VIA SHARED ONCOGENIC MECHANISMS. *Neuro-Oncology*, **2021**, 23, i13-i14	1	78
75	Development of Randomized Trials in Adults with Medulloblastoma-The Example of EORTC 1634-BTG/NOA-23. *Cancers*, **2021**, 13,	6.6	2
74	Second series by the Italian Association of Pediatric Hematology and Oncology of children and adolescents with intracranial ependymoma: an integrated molecular and clinical characterization with a long-term follow-up. *Neuro-Oncology*, **2021**, 23, 848-857	1	7
73	The genetic landscape of choroid plexus tumors in children and adults. *Neuro-Oncology*, **2021**, 23, 650-660	1	3
72	Current recommendations for clinical surveillance and genetic testing in rhabdoid tumor predisposition: a report from the SIOPE Host Genome Working Group. *Familial Cancer*, **2021**, 20, 305-316	3	5
71	Ultra high-risk PFA ependymoma is characterized by loss of chromosome 6q. *Neuro-Oncology*, **2021**, 23, 1360-1370	1	14
70	Predisposition to cancer in children and adolescents. *The Lancet Child and Adolescent Health*, **2021**, 5, 142-154	14.5	15
69	How we treat medulloblastoma in adults. *ESMO Open*, **2021**, 6, 100173	6	3
68	PATZ1 fusions define a novel molecularly distinct neuroepithelial tumor entity with a broad histological spectrum. *Acta Neuropathologica*, **2021**, 142, 841-857	14.3	7

67	Recurrent fusions in PLAGL1 define a distinct subset of pediatric-type supratentorial neuroepithelial tumors. *Acta Neuropathologica*, **2021**, 142, 827-839	14.3	5
66	The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets. *Cancer Discovery*, **2021**, 11, 2764-2779	24.4	22
65	Sarcoma classification by DNA methylation profiling. *Nature Communications*, **2021**, 12, 498	17.4	74
64	Clinically aggressive pediatric spinal ependymoma with novel MYC amplification demonstrates molecular and histopathologic similarity to newly described MYCN-amplified spinal ependymomas.. *Acta Neuropathologica Communications*, **2021**, 9, 192	7.3	0
63	cIMPACT-NOW update 7: advancing the molecular classification of ependymal tumors. *Brain Pathology*, **2020**, 30, 863-866	6	51
62	INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies. *BMC Cancer*, **2020**, 20, 523	4.8	11
61	Germline Elongator mutations in Sonic Hedgehog medulloblastoma. *Nature*, **2020**, 580, 396-401	50.4	47
60	The pediatric precision oncology study INFORM: Clinical outcome and benefit for molecular subgroups.. *Journal of Clinical Oncology*, **2020**, 38, LBA10503-LBA10503	2.2	9
59	EPEN-36. THE TREATMENT OUTCOME OF PAEDIATRIC SUPRATENTORIAL C11ORF95-RELA FUSED EPENDYMOMA: A COMBINED REPORT FROM E-HIT SERIES AND AUSTRALIAN NEW ZEALAND CHILDREN HAEMATOLOGY/ONCOLOGY GROUP. *Neuro-Oncology*, **2020**, 22, iii315-iii315	1	78
58	EPEN-18. CROSS-SPECIES GENOMICS IDENTIFIES GLI2 AS AN ONCOGENE OF C11orf95 FUSION-POSITIVE SUPRATENTORIAL EPENDYMOMA. *Neuro-Oncology*, **2020**, 22, iii311-iii311	1	78
57	EPEN-44. EXTRACELLULAR VESICLES OF SUPRATENTORIAL EPENDYMOMA RELA MEDIATE INTERACTIONS WITH CELLS OF THE TUMOR MICROENVIRONMENT. *Neuro-Oncology*, **2020**, 22, iii316-iii317	1	78
56	EPEN-39. CLINICAL STRATIFIED TREATMENT OF LOCALIZED PEDIATRIC INTRACRANIAL EPENDYMOMA WITH COMBINED LOCAL IRRADIATION AND CHEMOTHERAPY WITHIN THE PROSPECTIVE, MULTICENTER E-HIT TRIAL THE MOLECULAR SUBGROUP MATTERS. *Neuro-Oncology*, **2020**, 22, iii315-iii316	1	0
55	MBRS-68. SINGLE NUCLEUS RNA-SEQUENCING DECIPHERS INTRATUMORAL HETEROGENEITY IN MEDULLOBLASTOMA WITH EXTENSIVE NODULARITY (MBEN). *Neuro-Oncology*, **2020**, 22, iii410-iii410	1	78
54	Molecular characterization of histopathological ependymoma variants. *Acta Neuropathologica*, **2020**, 139, 305-318	14.3	20
53	YAP1-fusions in pediatric NF2-wildtype meningioma. *Acta Neuropathologica*, **2020**, 139, 215-218	14.3	24
52	Transcriptional profiling of medulloblastoma with extensive nodularity (MBEN) reveals two clinically relevant tumor subsets with VSNL1 as potent prognostic marker. *Acta Neuropathologica*, **2020**, 139, 583-596	14.3	6
51	Response to trametinib treatment in progressive pediatric low-grade glioma patients. *Journal of Neuro-Oncology*, **2020**, 149, 499-510	4.8	20
50	Single-Cell RNA-Seq Reveals Cellular Hierarchies and Impaired Developmental Trajectories in Pediatric Ependymoma. *Cancer Cell*, **2020**, 38, 44-59.e9	24.3	40

49	Comparison of tumor-associated YAP1 fusions identifies a recurrent set of functions critical for oncogenesis. *Genes and Development*, **2020**, 34, 1051-1064	12.6	21
48	Cerebrospinal Fluid Penetration and Combination Therapy of Entrectinib for Disseminated -Fusion Positive Pediatric High-Grade Glioma. *Journal of Personalized Medicine*, **2020**, 10,	3.6	8
47	YAP1 subgroup supratentorial ependymoma requires TEAD and nuclear factor I-mediated transcriptional programmes for tumorigenesis. *Nature Communications*, **2019**, 10, 3914	17.4	39
46	EPEN-04. CXorf67 MIMICS ONCOGENIC HISTONE H3 K27M MUTATIONS AND FUNCTIONS AS INTRINSIC INHIBITOR OF PRC2 FUNCTION IN AGGRESSIVE POSTERIOR FOSSA EPENDYMOMA. *Neuro-Oncology*, **2019**, 21, ii78-ii78	1	78
45	Brainstem biopsy in pediatric diffuse intrinsic pontine glioma in the era of precision medicine: the INFORM study experience. *European Journal of Cancer*, **2019**, 114, 27-35	7.5	28
44	EZHIP/CXorf67 mimics K27M mutated oncohistones and functions as an intrinsic inhibitor of PRC2 function in aggressive posterior fossa ependymoma. *Neuro-Oncology*, **2019**, 21, 878-889	1	65
43	Evaluation of Storage Tubes for Combined Analysis of Circulating Nucleic Acids in Liquid Biopsies. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	27
42	MYCN amplification drives an aggressive form of spinal ependymoma. *Acta Neuropathologica*, **2019**, 138, 1075-1089	14.3	51
41	Newly Diagnosed Metastatic Intracranial Ependymoma in Children: Frequency, Molecular Characteristics, Treatment, and Outcome in the Prospective HIT Series. *Oncologist*, **2019**, 24, e921-e929	5.7	6
40	EANO-EURACAN clinical practice guideline for diagnosis, treatment, and follow-up of post-pubertal and adult patients with medulloblastoma. *Lancet Oncology, The*, **2019**, 20, e715-e728	21.7	31
39	Diagnostics of pediatric supratentorial RELA ependymomas: integration of information from histopathology, genetics, DNA methylation and imaging. *Brain Pathology*, **2019**, 29, 325-335	6	30
38	The landscape of genomic alterations across childhood cancers. *Nature*, **2018**, 555, 321-327	50.4	603
37	Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling. *Nature*, **2018**, 553, 101-105	50.4	116
36	DNA methylation-based classification of central nervous system tumours. *Nature*, **2018**, 555, 469-474	50.4	992
35	Ependymoma. *Seminars in Neurology*, **2018**, 38, 104-111	3.2	27
34	DNA methylation-based classification of ependymomas in adulthood: implications for diagnosis and treatment. *Neuro-Oncology*, **2018**, 20, 1616-1624	1	32
33	Heterogeneity within the PF-EPN-B ependymoma subgroup. *Acta Neuropathologica*, **2018**, 136, 227-237	14.3	52
32	Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. *Lancet Oncology, The*, **2018**, 19, 785-798	21.7	159

31	Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas. *Acta Neuropathologica*, **2018**, 136, 211-226	14.3	111
30	Epidemiology, molecular classification and WHO grading of ependymoma. *Journal of Neurosurgical Sciences*, **2018**, 62, 46-50	1.3	18
29	Limitations of current models for testing the clinical potential of epigenetic inhibitors for treatment of pediatric ependymoma. *Oncotarget*, **2018**, 9, 36530-36541	3.3	6
28	Ependymoma **2018**, 177-192		1
27	EPEN-07. OVEREXPRESSION AND MUTATIONS OF CXORF67 IN INFANT-TYPE POSTERIOR FOSSA TYPE-A (PFA) EPENDYMOMAS. *Neuro-Oncology*, **2018**, 20, i74-i74	1	78
26	FGFR1:TACC1 fusion is a frequent event in molecularly defined extraventricular neurocytoma. *Acta Neuropathologica*, **2018**, 136, 293-302	14.3	29
25	A Mouse Ependymoma Model Provides Molecular Insights into Tumor Formation. *Cell Reports*, **2018**, 23, 3699-3700	10.6	
24	Genetic confirmation that ependymoma can arise as part of multiple endocrine neoplasia type 1 (MEN1) syndrome. *Acta Neuropathologica*, **2017**, 133, 661-663	14.3	8
23	Childhood cancer predisposition syndromes-A concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatric Oncology and Hematology. *American Journal of Medical Genetics, Part A*, **2017**, 173, 1017-1037	2.5	124
22	Recommendations for Cancer Surveillance in Individuals with RASopathies and Other Rare Genetic Conditions with Increased Cancer Risk. *Clinical Cancer Research*, **2017**, 23, e83-e90	12.9	77
21	Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome. *Clinical Cancer Research*, **2017**, 23, e38-e45	12.9	245
20	Telomerase activation in posterior fossa group A ependymomas is associated with dismal prognosis and chromosome 1q gain. *Neuro-Oncology*, **2017**, 19, 1183-1194	1	24
19	Molecular mechanisms and therapeutic targets in pediatric brain tumors. *Science Signaling*, **2017**, 10,	8.8	43
18	Multiple Endocrine Neoplasia and Hyperparathyroid-Jaw Tumor Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in Childhood. *Clinical Cancer Research*, **2017**, 23, e123-e132	12.9	43
17	The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants. *Acta Neuropathologica*, **2017**, 133, 5-12	14.3	202
16	Clinical and molecular subgroups of ependymoma in adulthood: An analysis of the German Glioma Network.. *Journal of Clinical Oncology*, **2017**, 35, 2038-2038	2.2	1
15	The GSK461364 PLK1 inhibitor exhibits strong antitumoral activity in preclinical neuroblastoma models. *Oncotarget*, **2017**, 8, 6730-6741	3.3	24
14	Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis. *Journal of Clinical Oncology*, **2016**, 34, 2468-77	2.2	113

13	New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. *Cell*, **2016**, 164, 1060-1072	36.2	483
12	Low-dose Actinomycin-D treatment re-establishes the tumoursuppressive function of P53 in RELA-positive ependymoma. *Oncotarget*, **2016**, 7, 61860-61873	3.3	22
11	Papillary Tumor of the Pineal Region: A Distinct Molecular Entity. *Brain Pathology*, **2016**, 26, 199-205	6	25
10	Telomere dysfunction and chromothripsis. *International Journal of Cancer*, **2016**, 138, 2905-14	7.5	34
9	Intraventricular etoposide safety and toxicity profile in children and young adults with refractory or recurrent malignant brain tumors. *Journal of Neuro-Oncology*, **2016**, 128, 463-71	4.8	11
8	MiR-34a deficiency accelerates medulloblastoma formation in vivo. *International Journal of Cancer*, **2015**, 136, 2293-303	7.5	32
7	Molecular dissection of ependymomas. *Oncoscience*, **2015**, 2, 827-8	0.8	14
6	Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups. *Cancer Cell*, **2015**, 27, 728-43	24.3	672
5	Neuroblastoma in dialog with its stroma: NTRK1 is a regulator of cellular cross-talk with Schwann cells. *Oncotarget*, **2014**, 5, 11180-92	3.3	19
4	The KDM1A histone demethylase is a promising new target for the epigenetic therapy of medulloblastoma. *Acta Neuropathologica Communications*, **2013**, 1, 19	7.3	23
3	Expression of NTRK1/TrkA affects immunogenicity of neuroblastoma cells. *International Journal of Cancer*, **2013**, 133, 908-19	7.5	16
2	Lysine-specific demethylase 1 restricts hematopoietic progenitor proliferation and is essential for terminal differentiation. *Leukemia*, **2012**, 26, 2039-51	10.7	141
1	Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas. *Neuro-Oncology*, **2012**, 14, 859-69	1	44